<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800447</url>
  </required_header>
  <id_info>
    <org_study_id>Zhaoke-NTL-2015-01</org_study_id>
    <nct_id>NCT02800447</nct_id>
  </id_info>
  <brief_title>Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <brief_summary>
    <textblock>
      1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD&#xD;
           regimens for patients with advanced Hodgkin's lymphoma.&#xD;
&#xD;
        2. To evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a confirmatory open-label, randomized, controlled, multicenter study. Recruited&#xD;
      subjects are to be randomized to treatment group and controlled group, with ratio of 1:1.&#xD;
      Treatment group will accept baseline BEACOPP regimen, while controlled group will accept ABVD&#xD;
      regimen.&#xD;
&#xD;
      The study design consisted of a screening phase of 1 week, a treatment phase of 24 or 32&#xD;
      weeks, and a post treatment follow-up of at least 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>45 months</time_frame>
    <description>Compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for in patients with advanced Hodgkin's lymphoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety as measured by changes of vital signs, ECG and AE number</measure>
    <time_frame>45 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Advanced Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>baseline BEACOPP regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlled group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABVD regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natulan</intervention_name>
    <description>Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Procarbazine hydrochloride capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABVD</intervention_name>
    <description>Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;</description>
    <arm_group_label>controlled group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is of age 18~65, both male and female;&#xD;
&#xD;
          -  Newly pathologically diagnosed with classical Hodgkin's lymphoma (lymphocyte depletion&#xD;
             type, lymphocyte rich type, nodular sclerosing type, and mixed cellularity type), who&#xD;
             had not accepted previous treatment;&#xD;
&#xD;
          -  Had stage IIB, III or IV disease, as assessed by the Ann Arbor classification;&#xD;
&#xD;
          -  ECOG≤2, life expectancy ≥3 month;&#xD;
&#xD;
          -  A negative serum pregnancy test required for sexually active women of childbearing&#xD;
             potential;&#xD;
&#xD;
          -  The subject voluntarily gives written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematopoietic function:&#xD;
&#xD;
               -  Leukocyte &lt;3,500/mm3（3.5×109/L）&#xD;
&#xD;
               -  Neutrophils &lt;1,500/mm3（1.5×109/L）&#xD;
&#xD;
               -  Platelets &lt;100,000/mm3（100×109/L）&#xD;
&#xD;
          -  Intolerance to any of the active ingredients and/or excipients in the study&#xD;
             medications;&#xD;
&#xD;
          -  Severe central nervous system disorders and mental illness;&#xD;
&#xD;
          -  Severe heart disease (congestive heart failure, uncontrolled hypertension, unstable&#xD;
             coronary artery disease, or myocardial infarction, or severe arrhythmia).&#xD;
             Echocardiography showed resting left ventricular ejection fraction (LVEF) &lt; 50%);&#xD;
&#xD;
          -  History of severe lung disease;&#xD;
&#xD;
          -  AST or ALT&gt;2.5×ULN，total bilirubin≥1.5×ULN，serum creatinine&gt;1.5×ULN (for subject with&#xD;
             liver metastases: AST or ALT&gt;5xULN, total bilirubin ≥ 3xULN);&#xD;
&#xD;
          -  Uncontrolled, systemic, active infection；&#xD;
&#xD;
          -  Positive serology to HIV;&#xD;
&#xD;
          -  HBsAg positive subjects can still be enrolled in the study, but researchers should&#xD;
             follow &quot;The consensus on the Treatment of Lymphoma with Hepatitis B Infections&quot; to&#xD;
             observe closely and/or provide prophylactic anti-HBV therapy (as per investigator's&#xD;
             decision);&#xD;
&#xD;
          -  Other previous or concomitant malignancy, except for basal cell carcinoma and/or&#xD;
             cervical carcinoma in situ;&#xD;
&#xD;
          -  The subject is receiving an investigational drug, or has participated in an&#xD;
             investigational study within 30 days prior to screening;&#xD;
&#xD;
          -  The subject is pregnant or lactating; or subjects of childbearing potential (both&#xD;
             women and man subjects) do not want to take effective contraceptive measures during&#xD;
             study period or within 3 months after study completes;&#xD;
&#xD;
          -  Investigators believe subjects not suitable to participate in the study for other&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

